Talkspace, Inc.
NASDAQ:TALKMedical - Care Facilities
+$0.01 today
- Market cap
- $879.44M
- Beta
- 1.07
- P/E (TTM)
- 749.9
- EPS (TTM)
- $0.01
Volume 2.41M
Average 2.55M
TALK Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Talkspace, Inc.NASDAQ: TALK
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development dips below year-ago levels
Q1 FY2026 research & development of $2.66M fell 19.7% year over year, behind the +17.1% change in trailing-twelve-month research & development. Sequentially, it rose 13.0% from the prior quarter. Over 3 fiscal years it compounded at -23.9% a year.
Context
- Research & development amounted to 4.2% of revenue in FY2025, down 1.4 pp from a year earlier.
- Research & development increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -19.7% toward the trailing-twelve-month pace of +17.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 9.54M USD
- Year-over-year change
- -9.2%
- 4-year CAGR
- -12.0%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.54M | -9.2% |
| FY2024 | 2024-12-31 | 10.51M | -40.2% |
| FY2023 | 2023-12-31 | 17.57M | -18.9% |
| FY2022 | 2022-12-31 | 21.66M | +36.1% |
| FY2021 | 2021-12-31 | 15.92M | — |
Research & Development vs competitors
How TALK compares with its peers on the latest reported figures
- TALK's LTM Mar 2026 research & development of $11.72M is the 6th highest of the 11 companies compared; the peer median is $7.63M.
- Its year-over-year change of +17.1% is the 2nd highest of 6, against a peer median of -6.9%.
- Research & development amounts to 4.9% of revenue for TALK, versus a peer median of 2.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $110.07M | -12.0% | +22.1% | — | |
| LTM Dec 2025 | $48.42M | — | — | 41.8% | |
| LTM Mar 2026 | $36.54M | +41.7% | -17.9% | 12.2% | |
| LTM Mar 2026 | $22.9M | -6.9% | -8.9% | 3.2% | |
| LTM Mar 2026 | $15.04M | +14.4% | +8.5% | 37.0% | |
| LTM Mar 2026 | $11.72M | +17.1% | -23.9% | 4.9% | |
NNNNAnbio Biotechnology Class A Ordinary Shares | FY2025 | $227.19K | -50.0% | +4.3% | 2.3% |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding TALK) | $7.63M | -6.9% | +4.3% | 2.3% | |
Competitors are the stored peer set for TALK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 113.67M | 119.57M | 150.05M | 187.59M | 228.87M |
| Cost of Revenue | 46.9M | 59.23M | 75.67M | 101.76M | 130.52M |
| Gross Profit | 66.77M | 60.34M | 74.38M | 85.84M | 98.35M |
| Gross Margin | 58.7% | 50.5% | 49.6% | 45.8% | 43.0% |
| Research & Development | 15.92M | 21.66M | 17.57M | 10.51M | 9.54M |
| Selling, General & Admin | 135.41M | 109.11M | 73.86M | 73.28M | 75.57M |
| Operating Expenses | 160.7M | 137.36M | 97.59M | 90.33M | 95.2M |
| Depreciation & Amortization | 1.97M | 1.36M | 1.2M | 859K | 2.88M |
| EBITDA | (60.72M) | (78.06M) | (17.77M) | 2.1M | 11.24M |
| EBITDA Margin | -53.4% | -65.3% | -11.8% | 1.1% | 4.9% |
| Operating Income | (93.92M) | (77.02M) | (23.21M) | (4.5M) | 3.15M |
| Operating Margin | -82.6% | -64.4% | -15.5% | -2.4% | 1.4% |
| Interest Income | 31.23M | 3.74M | 4.25M | 5.74M | 5.22M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 31.23M | (2.39M) | 4.25M | 5.74M | 5.22M |
| Income Before Tax | (62.7M) | (79.42M) | (18.96M) | 1.24M | 8.37M |
| Pre-Tax Margin | -55.2% | -66.4% | -12.6% | 0.7% | 3.7% |
| Income Tax Expense | 47K | 254K | 218K | 94K | 574K |
| Net Income | (62.74M) | (79.67M) | (19.18M) | 1.15M | 7.79M |
| Net Margin | -55.2% | -66.6% | -12.8% | 0.6% | 3.4% |
| EPS (Basic) | (0.72) | (0.51) | (0.12) | 0.01 | 0.05 |
| EPS (Diluted) | (0.72) | (0.51) | (0.12) | 0.01 | 0.04 |
| Weighted Avg Shares | 154.08M | 156.89M | 165.04M | 168.91M | 168.43M |
| Weighted Avg Shares (Diluted) | 154.08M | 156.89M | 165.04M | 176.5M | 173.75M |
Talkspace, Inc.
NASDAQ:TALK
Intrinsic Alpha fair value
Locked
Current Price
$5.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.